Navigation Links
Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax

treatments began 24 hours after exposure to B. anthracis spores. Survival rates at 30 days post- exposure were as follows: 90 percent survival with CIP and 100 percent survival with ORI treatment at doses equal to or greater than 3 mg/kg intraperitoneally (multiple dose) or 50 mg/kg intravenously (single dose).

A follow-up experiment showed that ORI or CIP provided significant survival rates even when the start of treatment was delayed to either 36 or 48 hours post-exposure to spores (i.e., until symptoms had begun to appear). In this experiment, ORI was administered at 10 mg/kg once every 2 days while CIP was administered at 30 mg/kg twice daily. Treatments were provided intraperitoneally for 14 days and survivorship was measured at 30 days.

In addition, a single 50 mg/kg intravenous dose of ORI administered 24 hours prior to anthrax exposure provided a 100 percent survival rate at 30 days.

Researchers at USAMRIID and Targanta concluded that their results provide impetus for investigation of whether ORI could serve as an effective therapy for anthrax exposure, requiring fewer doses compared to CIP, or perhaps even as a potential prophylactic agent.

B. anthracis, a bacterium that forms spores and causes anthrax, has been recognized for more than 60 years as a potential biological warfare agent. Such was the case in 2001, when B. anthracis spores were distributed through the U.S. Postal Service, causing 22 cases of anthrax, including five deaths. If treated promptly B. anthracis usually responds effectively to several antibiotics including penicillin, doxycycline and fluoroquinolones (including ciprofloxacin). Though ciprofloxacin is the current standard of treatment for exposure, anthrax has the possibility of being engineered to be multi-drug resistant, which would complicate treatment. The World Health Organization estimates that 50 kg of B. anthracis spores effectively released in a population of 500,000 people would result in 95,000
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:7/22/2014)... -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN ... first lots of Fluzone ® (Influenza Vaccine) for the ... U.S. Food and Drug Administration (FDA) for distribution. The lots ... at least 65 million doses of seasonal influenza vaccine manufactured ... care providers and pharmacies in August. The ...
(Date:7/22/2014)... 2014  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... dosing of patients in its ongoing Phase 2 trial ... under the revised clinical protocol agreed to with the ... of Halozyme,s proprietary recombinant human hyaluronidase under development for ... "Our diligent effort to rapidly re-initiate patient ...
(Date:7/22/2014)... PHILADELPHIA ,  July 22, 2014 /PRNewswire/ ... business of Thomson Reuters , the world,s ... and professionals, today announced Cortellis Clinical ... database, marked an industry-first milestone with the ... thus providing pharmaceutical professionals with greater and ...
Breaking Medicine Technology:Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3
... Inc. the leading provider of computerized maintenance management ... to announce the latest release of TMS 2012.5.5.  ... have included a number of new features and ... The new release of TMS will continue ...
... NEW YORK, Feb. 29, 2012  TheraBiogen, Inc. (OTC BB: ... for aiding in the relief of allergies, cold and ... its Thera Max® Cold and Flu brand is receiving ... The Company is taking its new homeopathic product, Thera ...
Cached Medicine Technology:Four Rivers Software Systems Launches TMS 2012.5.5 2Thera Max® Cold and Flu Brand Receives Great Benefits from Its Ongoing Social Media Marketing Awareness Program 2Thera Max® Cold and Flu Brand Receives Great Benefits from Its Ongoing Social Media Marketing Awareness Program 3
(Date:7/22/2014)... 22, 2014 Air Conditioning & Heating ... an authorized Daikin comfort pro dealer. This means that ... heating and cooling system equipment. Only a select few ... reviewed before being approved. , Daikin co-developed an R-410A ... Split System Air Conditioning Market. They are also the ...
(Date:7/22/2014)... 2014 United Benefit Advisors (UBA), the ... Les McPhearson, an insurance veteran with more than 15 ... and be based in the company's Chicago office. , ... that Les chose to accept this important, strategic position ... the many challenges facing UBA and its Partners as ...
(Date:7/22/2014)... By Steven Reinberg ... -- Women who are obese during pregnancy may be more ... new review suggests. "We found that, compared with children ... overweight or obese during pregnancy had up to 20 to ... Erick Forno, an assistant professor of pediatrics at Children,s Hospital ...
(Date:7/22/2014)... the Clean Plate Club you eat pretty much everything ... A new Cornell University study shows that the average adult ... or her plate. "If you put it on ... Ph.D., author of the forthcoming book, Slim by Design, Professor ... Lab. , Wansink and co-author Katherine Abowd Johnson analyzed 1179 ...
(Date:7/22/2014)... July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014”) championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). , ...
Breaking Medicine News(10 mins):Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... pretext for multinational corporations to take control of the precious ... With sales of over $35 billion worldwide in the ... buy up pristine springs in some of the country's most ... one-third of the U.S. market and sells 70 different brand ...
... overdose during pregnancy could be harmful, according to an Iranian ... combat anemia in pregnancy but many women take extra iron. ... carry enough oxygen due to low number of red blood ... carry normal amounts of oxygen. Common symptoms of anemia include ...
... for Inclusive Communities (CAIC) has recently joined the fight ... the majority of state and national disability rights organizations ... group that works on behalf of groups with developmental ... as a new national AP/Ipsis poll was released indicating ...
... the Pharmaceutical Research and Manufacturers of America (PhRMA) finds ... of the three leading causes of death of Americans ... currently in clinical trials or under review by the ... and stroke are still leading causes of death in ...
... advent of a possible new blockbuster drug and greater ... drug addictions, global sales of smoking cessation and ... little over $1.1 billion in 2005 to more than ... Addiction Treatments: A World Market Analysis, a new study ...
... on cardiometabolic risk factors beyond those expected from weight ... not be due to the drug itself, reports an ... Bulletin (DTB). ,Advertisements for rimonabant (sold ... an estimated 50% of the effects on cardiometabolic ...
Cached Medicine News:Health News:Multinationals Exploit Groundwater Sources, and People Suffer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 3Health News:Multinationals Exploit Groundwater Sources, and People Suffer 4Health News:Multinationals Exploit Groundwater Sources, and People Suffer 5Health News:More Than 270 Medicines in Testing for Heart Disease and Stroke 2Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2
... matrix constructed of cross-linked collagen fibers ... through a proprietary 360 accretion process. ... aspirate, Healos provides an excellent environment ... differentiation. The hydroxyapatite-coated collagen microfibers in ...
Sharp Weitlaner Retractor....
Weitlaner retractor, blunt....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
Medicine Products: